¥200M raised
11-50 employees
Series A
AI/ML Xellar Biosystems (耀速科技, also trading as Xellar Technology) is a Chinese biotech building an AI + organ-on-a-chip closed-loop platform dubbed 3D-Wet-AI for preclinical drug testing. Founded in 2021, it is the only Chinese company selected for the US FDA's program to validate new alternative methods (NAMs) replacing animal testing, and maintains strategic partnerships with XtalPi on quantum-AI drug design and with Korea's WOOJUNG BIO on hybrid human-OoC plus animal preclinical platforms.
Raised
¥200M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Boston, Massachusetts
United States